Gynecologic Cancer
Opinion
Guidelines for today and tomorrow
Dr. Alan P. Lyss comments on guidelines for genetic testing in epithelial ovarian cancer and data that support a reexamination of colorectal...
From the Journals
Proteogenomics provides molecular insights into endometrial carcinoma
Analyses have revealed potential therapeutic targets and methods of optimizing therapy for endometrial carcinoma.
Conference Coverage
IFN-activated monocytes show early promise for ovarian cancer
ORLANDO - Two of 11 patients achieved a partial response, and there were no grade 4-5 adverse events.
News
FDA: Cell phones still look safe
The available evidence does not suggest a causal link between cell phone use and cancer, according to the FDA.
From the Journals
Any dose of HPV vaccine is better than none
Large retrospective study shows similar cervical cancer protection in girls and women given 1, 2, or 3 doses of HPV vaccine between 15 and 19...
From the Journals
Lidocaine-prilocaine cream tops lidocaine injections for vulvar biopsy pain
Studies have pitted the cream against the injection before, but they did not compare patients’ maximal pain scores.
From the Journals
Vaccinating most girls could eliminate cervical cancer within a century
A model suggests that universal girls-only HPV vaccination could prevent 61 million cases of cervical cancer.
From the Journals
Global project reveals cancer’s genomic playbook
The Pan-Cancer Analysis of Whole Genomes, an international collaboration, reveals the complexity of oncogenesis.
From the Journals
Preoperative CT shows little value in early vulvar SCC
There was no significant difference in survival or groin node recurrence between patients who underwent preoperative CT and patients who did not...
From the Journals
Ovarian cancer survival varies between high-income countries
The 3-year net survival was highest in Norway and lowest in Ireland.
From the Journals
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.